Year: 2018
Type: article
Abstract: Unlike many conventional cancers with preferential patterns of oncogenic genetic alterations, TRK fusions resulting from NTRK1/2/3 genetic alterations drive oncogenic transformations in more than 20 different malignancies over diverse tissue/cell lineages, in both children and adults. A recent "basket" study of larotrectinib, a TRK inhibitor, has demonstrated significant efficacy in TRK fusion-positive tumors of all types from infants to the elderly. Here, we discuss the larotrectinib study and perspectives and challenges in developing "tumor-agnostic" targeted therapies in rare tumors.
Source: Journal of Hematology & Oncology
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,990
Awards: G1140985894, G2105990674, The MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity Center, G3122137126, G3239159112, G4119534169, G5850682332, DECIPHERING THE ROLE OF THE TMPRSS2-ERG FUSION IN THE PATHOGENESIS OF PROSTATE CANCER: MECHANISTIC STUDIES AND IN VIVO MODELING, G623960002, An integrative approach to target lineage-specific oncogenic transcription factor, G644011781, G7488958404, G856420729, NOVEL THERAPEUTIC DEVELOPMENT OF NF1-ASSOCIATED MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST), Cancer Center Support Grant, SPORE in Prostate Cancer, G99616726
OpenAlex ID: W2806697314